CepTor Deal With Ferring For Infant Respiratory Drug Is Contingent Upon FDA Agreement On Phase II Endpoints
This article was originally published in The Pink Sheet Daily
Executive Summary
After CepTor purchases superoxide dismutase from Ferring, the firm will repeat a Phase IIb study using new endpoints.